- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06165341
Étude pour en savoir plus sur l'innocuité du Fazirsiran et s'il peut aider les personnes atteintes d'une maladie hépatique alpha-1 antitrypsine avec de légères cicatrices hépatiques (fibrose)
Une étude de phase 3 randomisée, en double aveugle, contrôlée par placebo, pour évaluer l'innocuité et l'efficacité du fazirsiran dans le traitement de la maladie hépatique associée au déficit en alpha-1 antitrypsine avec fibrose METAVIR de stade F1
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver.
People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.
After their last clinic visits, participants will have two choices:
- They can complete this study and return to the clinic 3 and 6 months later so the study doctors can check for side effects; OR
- If they meet the rules, they can join another study (called extension or continuation study), in which they will receive fazirsiran every 3 months and will continue to have health checks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Takeda Contact
- Numéro de téléphone: +1-877-825-3327
- E-mail: medinfoUS@takeda.com
Lieux d'étude
-
-
-
Aachen, Allemagne, 52074
- Recrutement
- Universitätsklinikum der RWTH Aachen
-
Chercheur principal:
- Pavel Strnad
-
Contact:
- Numéro de téléphone: +492418035324
- E-mail: pstrnad@ukaachen.de
-
Berlin, Allemagne, 13353
- Recrutement
- Charité - Campus Virchow-Klinikum
-
Contact:
- Site Contact
- Numéro de téléphone: +4939450553022
- E-mail: frank.tacke@charite.de
-
Chercheur principal:
- Frank Tacke
-
Hanover, Allemagne, 30625
- Recrutement
- Hannover Medical School
-
Chercheur principal:
- Heiner Wedemeyer
-
Contact:
- Site Contact
- Numéro de téléphone: +495115322730
-
Tübingen, Allemagne, 72076
- Recrutement
- Universitätsklinikum Tübingen
-
Chercheur principal:
- Christoph Berg
-
Contact:
- Site Contact
- Numéro de téléphone: +4970712977661
-
-
-
-
-
Antwerp, Belgique, 2650
- Recrutement
- UZ Antwerpen
-
Chercheur principal:
- Sven Francque
-
Contact:
- Site Contact
- Numéro de téléphone: +3238213323
- E-mail: sven.francque@uza.be
-
Leuven, Belgique, 3000
- Recrutement
- UZ Leuven
-
Chercheur principal:
- Jef Verbeek
-
Contact:
- Site Contact
- Numéro de téléphone: +328888888888
- E-mail: jef.verbeek@uzleuven.be
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 3A9
- Recrutement
- Inspiration Research Limited
-
Chercheur principal:
- Kenneth Chapman
-
Contact:
- Site Contact
- Numéro de téléphone: (416) 944-9602
-
-
-
-
-
Seville, Espagne, 41018
- Recrutement
- Hospital Universitario Virgen del Rocio - PPDS
-
Contact:
- Site Contact
- Numéro de téléphone: +34955012065
- E-mail: mromerogomez@us.es
-
Chercheur principal:
- Manuel Romero Gómez
-
-
-
-
-
Lyon, France, 69317
- Recrutement
- Hôpital de La Croix Rousse
-
Contact:
- Site contact
- Numéro de téléphone: +33145596790
- E-mail: teresa.antonini@aphp.fr
-
Chercheur principal:
- Teresa Antonini
-
Rennes, France, 35000
- Recrutement
- Hopital PONTCHAILLOU CHU de Rennes
-
Contact:
- Site Contact
- Numéro de téléphone: +33299284297
- E-mail: edouard.bardou-jacquet@chu-rennes.fr
-
Chercheur principal:
- Edouard Bardou-Jacquet
-
Val-de-Marne, France, 94800
- Recrutement
- Hôpital Paul Brousse
-
Contact:
- Site Contact
- Numéro de téléphone: +33145593336
- E-mail: audrey.coilly@aphp.fr
-
Chercheur principal:
- Audrey Coilly
-
-
-
-
-
Pavia, Italie, 27100
- Recrutement
- Fondazione IRCCS Policlinico San Matteo
-
Chercheur principal:
- Angelo Corsico
-
Contact:
- Site Contact
- Numéro de téléphone: +390382503777
-
-
-
-
-
Graz, L'Autriche, 8036
- Recrutement
- LKH-Universitätsklinikum Graz
-
Contact:
- Site Contact
- Numéro de téléphone: +4331638580287
- E-mail: martin.wagner@medunigraz.at
-
Chercheur principal:
- Martin Wagner
-
Klagenfurt, L'Autriche, 9020
- Recrutement
- KABEG - Klinikum Klagenfurt Am Wörthersee
-
Chercheur principal:
- Markus Peck-Radosavljevic
-
-
-
-
-
Braga, Le Portugal, 4710-243
- Recrutement
- CCA Hospital Braga
-
Chercheur principal:
- Carla Rolanda
-
Funchal, Le Portugal, 9000-168
- Recrutement
- Hospital Dr. Nélio Mendonça
-
Chercheur principal:
- Vitor Pereira
-
Contact:
- Site Contact
- Numéro de téléphone: (351) 291-7056 x00
-
Porto, Le Portugal, 4099-001
- Recrutement
- Centro Hospitalar de Universitário de Santo António E.P.E
-
Contact:
- Site Contact
- Numéro de téléphone: +351918000000
-
Chercheur principal:
- Luís Maia
-
-
-
-
-
Mysłowice, Pologne, 41-400
- Retiré
- ID Clinic Arkadiusz Pisula
-
-
-
-
-
London, Royaume-Uni, SE5 9RS
- Recrutement
- King's College Hospital
-
Chercheur principal:
- Aftab Ala
-
Contact:
- Site Contact
- Numéro de téléphone: +442032993506
-
-
-
-
-
Bern, Suisse, 3010
- Recrutement
- Universitätsspital Bern
-
Chercheur principal:
- Guido Stirnimann
-
Contact:
- Site Contact
- Numéro de téléphone: +41442663568
-
-
-
-
-
Huddinge, Suède, 14186
- Recrutement
- Karolinska Universitetssjukhuset Huddinge
-
Contact:
- Site Contact
- Numéro de téléphone: +46858580000
-
Chercheur principal:
- Staffan Wahlin
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85013-4224
- Recrutement
- St Joseph's Hospital and Medical Center
-
Chercheur principal:
- Justin Reynolds
-
Contact:
- Site Contact
- Numéro de téléphone: 602-274-7195
-
Phoenix, Arizona, États-Unis, 85054-4502
- Recrutement
- Mayo Clinic - PPDS
-
Chercheur principal:
- Hugo Vargas
-
Contact:
- Site Contact
- Numéro de téléphone: 480-301-6990
- E-mail: vargas.hugo@mayo.edu
-
Tucson, Arizona, États-Unis, 85724-0001
- Recrutement
- University of Arizona Thomas D. Boyer Liver Institute
-
Contact:
- Site Contact
- Numéro de téléphone: 520-626-3005
- E-mail: gdblock@deptofmed.arizona.edu
-
Chercheur principal:
- Geoffrey Block
-
-
California
-
La Jolla, California, États-Unis, 92037-1337
- Recrutement
- University of California San Diego
-
Chercheur principal:
- Rohit Loomba
-
Contact:
- Site Contact
- Numéro de téléphone: 858-534-2555
- E-mail: roloomba@health.ucsd.edu
-
Los Angeles, California, États-Unis, 90095-3075
- Recrutement
- UCLA Pulmonary and Critical Care
-
Chercheur principal:
- Igor Barjaktarevic
-
Contact:
- Site Contact
- Numéro de téléphone: 310-825-8061
-
San Francisco, California, États-Unis, 94143-2203
- Recrutement
- University of California Benioff Children's Hospital
-
Chercheur principal:
- Philip Rosenthal
-
Contact:
- Site Contact
- Numéro de téléphone: 415-476-5892
- E-mail: PROSENTH@ucsf.edu
-
-
Colorado
-
Colorado Springs, Colorado, États-Unis, 80907
- Recrutement
- Peak Gastroenterology Associates
-
Chercheur principal:
- Bhaktasharan Patel
-
Contact:
- Site Contact
- Numéro de téléphone: 719-636-1201
-
-
Florida
-
Miami, Florida, États-Unis, 33136
- Recrutement
- Schiff Center for Liver Diseases/University of Miami
-
Chercheur principal:
- Eugene Schiff
-
Contact:
- Site Contact
- Numéro de téléphone: 305-243-5185
- E-mail: idsresearch@med.miami.edu
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202-2266
- Recrutement
- Indiana University School of Medicine-Indianapolis
-
Chercheur principal:
- Raj Vuppalanchi
-
Contact:
- Site Contact
- Numéro de téléphone: 317-278-4607
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242-1009
- Recrutement
- University Of Iowa Hospitals And Clinics
-
Chercheur principal:
- Tomohiro Tanaka
-
Contact:
- Site Contact
- Numéro de téléphone: 319-356-2577
- E-mail: Tomohiro-tanaka@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02118-2335
- Recrutement
- Boston Medical Center
-
Chercheur principal:
- Arpan Mohanty
-
Contact:
- Site Contact
- Numéro de téléphone: 617-638-6525
- E-mail: arpan.mohanty@bmc.org
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- University of Michigan Hospital - 1500 E Medical Center Dr
-
Chercheur principal:
- Robert Fontana
-
Contact:
- Site Contact
- Numéro de téléphone: 734-232-3741
-
Novi, Michigan, États-Unis, 48377-3600
- Recrutement
- Henry Ford Health System
-
Chercheur principal:
- Stuart Gordon
-
Contact:
- Site Contact
- Numéro de téléphone: 248-344-6688
- E-mail: sgordon3@hfhs.org
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic PPDS
-
Chercheur principal:
- Harmeet Malhi
-
Contact:
- Site Contact
- Numéro de téléphone: 507-284-0141
-
-
New York
-
New York, New York, États-Unis, 10016-6402
- Recrutement
- NYU Langone Medical Center
-
Chercheur principal:
- Viviana Figueroa Diaz
-
Contact:
- Site Contact
- Numéro de téléphone: 212-263-3643
- E-mail: viviana.figueroadiaz@nyumc.org
-
New York, New York, États-Unis, 10032-3722
- Recrutement
- Columbia University Irving Medical Center
-
Chercheur principal:
- Monica Goldklang
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106-1716
- Recrutement
- University Hospitals Cleveland Medical Center
-
Chercheur principal:
- Seth Sclair
-
Contact:
- Site Contact
- Numéro de téléphone: 216-983-0879
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033-2360
- Recrutement
- Penn State Health Milton S. Hershey Medical Center
-
Chercheur principal:
- Timothy Craig
-
Contact:
- Site Contact
- Numéro de téléphone: 717-531-7532
- E-mail: tcraig@pennstatehealth.psu.edu
-
-
Texas
-
San Antonio, Texas, États-Unis, 78215
- Recrutement
- Texas Liver Institute American Research Corporation
-
Chercheur principal:
- Eric Lawitz
-
Contact:
- Site Contact
- Numéro de téléphone: 210-253-3426
- E-mail: lawitz@txliver.com
-
-
Virginia
-
Newport, Virginia, États-Unis, 23602-4414
- Recrutement
- Bon Secours St. Mary's Hospital
-
Contact:
- Site Contact
- Numéro de téléphone: 804-977-8920
- E-mail: mitchell_shiffman@bshsi.org
-
Chercheur principal:
- Mitchell Schiffman
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- In the opinion of the investigator, the participant is capable of understanding and fully complying with the protocol requirements and adhering to the protocol schedule.
- The participant is able to read, understand, and complete the study questionnaires electronically per the investigator's judgment.
- The participant signs and dates a written Informed Consent Form (ICF). Any required privacy authorization should also be signed before the initiation of any study procedures.
- The participant, of any sex, is aged 18 to 75 years, inclusive.
- The participant must have a diagnosis of the protease inhibitor Z mutation (PiZZ) genotype AATD. A diagnosis of PiZZ from source-verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.
- The participant's liver biopsy core samples collected as per protocol requirements.
- The participant has evidence of METAVIR stage F1 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading from a previous biopsy conducted within 1 year before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.
- The participant has a pulmonary status that meets the protocol requirements.
- It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).
- Any participant who is taking statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or beta-1 selective adrenergic receptor inhibitors must have been receiving a stable dose of these medications for at least 8 weeks before randomization. All attempts are to be made for the participant to continue the same dose of the medication for the duration of study participation.
- An adult participant must have a body mass index (BMI) greater than or equal to (>=) 18 kilogram per meter square (kg/m^2).
- The participant has a 12-lead electrocardiogram at screening that, in the opinion of the investigator, has no abnormalities that could compromise the participant's safety in this study.
- The participant is a nonsmoker.
- If the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to [<=10] milligrams per day [mg/d] or its equivalent), the doses of the participant's medications must have remained unchanged for >=4 weeks before screening.
- The participant must have suitable venous access for blood sampling.
- A person of childbearing potential (POCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 before dosing.
- The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study and for 6 months after the last dose of study medication. The participant must not donate sperm for at least 6 months after the last dose of study medication.
Exclusion criteria:
- The participant has evidence of >= F2 fibrosis based on liver biopsy during the screening period.
- The participant has a history of liver decompensating events.
- The participant has a history of varices based on a previous esophagogastroduodenoscopy.
- The participant has portal vein thrombosis.
- The participant has undergone a prior trans-jugular portosystemic shunt procedure.
- The participant has evidence of other forms of chronic liver diseases.
- The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (>) 1 year may be enrolled. Individual cases may be discussed with the medical monitor for guidance.
- The participant has an abnormal finding of clinical relevance at the screening evaluation and before administration of the first dose of study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results.
- The participant has any laboratory abnormalities at screening and before the first dose of the study drug that meet protocol parameters.
- The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.
- The participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months prior to screening, unless, in the opinion of the investigator, the participant has achieved clinical recovery with pulmonary function returned to baseline. Individual cases may be discussed with the medical monitor for guidance.
- The participant has a history of frequent pulmonary exacerbations (>=2 moderate or severe exacerbations within 52 weeks before screening).
- The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened after the clinical resolution of an exacerbation).
- The participant is receiving long-term, around-the-clock oxygen supplementation or supplemental oxygen with continuous positive airway pressure (CPAP) or bilevel positive airway pressure for acute respiratory failure. The following conditions are allowable for the participant to enter screening: short-term use of oxygen supplementation (example, for the management of acute chronic obstructive pulmonary disease [COPD] exacerbation) or CPAP for obstructive sleep apnea.
- The participant has human immunodeficiency virus (HIV) infection as shown by the presence of anti-HIV antibody (seropositive).
- The participant is seropositive for hepatitis B virus (HBV surface antigen positive and/or HBV core antibody positive without HBV surface antibody at screening) or hepatitis C virus (HCV) (detectable HCV Ribonucleic Acid [RNA] at screening). Cured HCV (positive antibody test without detectable HCV RNA for at least 6 months after treatment) is acceptable.
- The participant has unstable, poorly controlled, or severe hypertension. Participants may be rescreened once their blood pressure (BP) is successfully controlled.
- The participant has a history of ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if they participate in the study, in the opinion of the investigator. Examples of significant ECG abnormalities include: torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG.
- The participant has symptomatic heart failure (per New York Heart Association guidelines), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction less than [<] 20 percent [%]), transient ischemic attack, or cerebrovascular accident within 6 months before screening.
- The participant has a history of major surgery within 12 weeks of screening (or longer, at the discretion of the investigator).
- The participant has a history of more than moderate alcohol consumption within 12 months before the screening visit.
- The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.
- The participant has previously been treated with fazirsiran or any other RNA interference (RNAi) for alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
- The participant has a history of hypersensitivity or allergies with any associated excipients of fazirsiran.
- The participant has received an investigational agent or device within 30 days, or 5 half-lives, whichever is longer, before the dosing of study medication or is currently participating in an investigational study involving a therapeutic intervention.
- The participant has donated >=500 milliliter (mL) of blood within 1 month of the administration of study treatment.
- The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk. The participant has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurologic, psychiatric, gastrointestinal (GI), systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
- The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 6 months before screening, or is taking chronic anticoagulants.
- This participant is unable to return for all scheduled study visits.
- The participant has symptomatic confirmed coronavirus disease 2019 (COVID-19) that, in the opinion of the investigator, does not resolve during screening; however, enrollment may be temporarily delayed at the discretion of the investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation. Individual cases may be discussed with the medical monitor for guidance.
- The participant is a study site employee involved in the conduct of this study, an immediate family member (example, spouse, parent, child, sibling), is in a dependent relationship with study site employee who is involved in the conduct of this study or may consent under duress.
- The participant takes or is required to take excluded medications.
- The participant is pregnant or breastfeeding or intending to become pregnant before participating in this study, during the study, or within 6 months after last dose of the study drug; or the participant is intending to donate ova during such time period.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Fazirsiran 200 mg
Participants will receive fazirsiran 200 milligrams (mg), injection, subcutaneously on Day 1, at Week 4 and then every 12 weeks (Q12W) for up to Week 100. |
Fazirsiran will be injected subcutaneously.
Autres noms:
|
|
Comparateur placebo: Placebo
Participants will receive fazirsiran matching placebo injection, subcutaneously on Day 1, at Week 4 and Q12W for up to Week 100. |
Fazirsiran matching placebo. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Délai: From start of study drug administration up to end of study (EOS) (Week 124)
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported. |
From start of study drug administration up to end of study (EOS) (Week 124)
|
|
Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function Parameters
Délai: From start of study drug administration up to EOS (Week 124)
|
Standard pulmonary function parameters will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion. |
From start of study drug administration up to EOS (Week 124)
|
|
Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung Densitometry
Délai: Baseline up to Week 100
|
Change from baseline in whole lung 15th percentile density as measured by CT lung densitometry will be assessed. |
Baseline up to Week 100
|
|
Number of Participants With Clinically Significant Changes in Vital Signs
Délai: From start of study drug administration up to EOS (Week 124)
|
Vital signs include body temperature, respiratory rate, blood pressure (systolic and diastolic), pulse (beats per minute) and pulse oximetry. Clinical significance of vital signs will be determined at the investigator's discretion. |
From start of study drug administration up to EOS (Week 124)
|
|
Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Délai: From start of study drug administration up to EOS (Week 124)
|
12-lead ECG will be evaluated. Any clinically significant change in ECG assessments will be determined at the investigator's discretion. |
From start of study drug administration up to EOS (Week 124)
|
|
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Délai: From start of study drug administration up to EOS (Week 124)
|
Laboratory parameters assessments include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion. |
From start of study drug administration up to EOS (Week 124)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in Serum Z-AAT Protein Over Time to Week 106
Délai: Baseline up to Week 106
|
Change From Baseline in Serum Z-AAT Protein will be assessed. |
Baseline up to Week 106
|
|
Percent Change From Baseline in Intrahepatic Liver Z-AAT Protein at Week 106
Délai: Baseline up to Week 106
|
Percent change from baseline in intrahepatic liver Z-AAT protein will be assessed. |
Baseline up to Week 106
|
|
Change From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 106
Délai: Baseline up to Week 106
|
Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy will be assessed. |
Baseline up to Week 106
|
|
Number of Participants with No Change or Decrease From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by PAS+D Staining at Week 106
Délai: Baseline up to Week 106
|
Number of participants with no change or decrease from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining will be reported. |
Baseline up to Week 106
|
|
Change From Baseline in Intrahepatic Portal Inflammation Score in Liver Biopsy at Week 106
Délai: Baseline up to Week 106
|
Change in portal inflammation score in liver biopsy is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. |
Baseline up to Week 106
|
|
Number of Participants with No Change or Decrease From Baseline in Intrahepatic Portal Inflammation Score at Week 106
Délai: Baseline up to Week 106
|
No Change or decrease in portal inflammation score is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. Number of Participants with no change or decrease from baseline in intrahepatic portal inflammation score will be reported. |
Baseline up to Week 106
|
|
Number of Participants With No Change or Decrease From Baseline in Histologic Fibrosis Score (Meta-analysis of Histological Data in Viral Hepatitis [METAVIR] Staging) at Week 106
Délai: Baseline up to Week 106
|
No change or decrease in histologic fibrosis (METAVIR staging) will be assessed using a fibrosis score of F0-F4, where higher scores mean a worse result. Number of participants with no change or decrease from baseline in histologic fibrosis score (by [METAVIR] staging) at Week 106 will be reported. |
Baseline up to Week 106
|
|
Change From Baseline in Vibration-Controlled Transient Elastography (VCTE)-Derived Liver Stiffness
Délai: Baseline up to Week 106
|
Change from baseline in VCTE-derived liver stiffness will be assessed. |
Baseline up to Week 106
|
|
Change From Baseline in Markers of Liver Injury
Délai: Baseline up to Week 106
|
Change from baseline in marker (alanine aminotransferase [ALT], aspartate aminotransferase [AST], glutamyl transferase [GGT]) of liver injury will be assessed. |
Baseline up to Week 106
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Study Director, Takeda
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladies génétiques, innées
- Maladies des voies respiratoires
- Maladies du système digestif
- Maladies pulmonaires
- Maladies du foie
- Emphysème sous-cutané
- Emphysème
- Maladies et anomalies congénitales, héréditaires et néonatales
- Conditions pathologiques, signes et symptômes
- carence en alpha 1-assine
Autres numéros d'identification d'étude
- TAK-999-3002
- 2023-504198-19-00 (Ctis: EU CTIS)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Critères d'accès au partage IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .